The effect of olfactory training and vitamin A in the olfactory loss of patients with covid-19.
IRCT; 2021-02-13; TrialID: IRCT20210205050247N1
Clinical Trial Register
| ICTRP | ID: ictrp-IRCT20210205050247N1
ABSTRACT
Condition
olfactory loss.Other disturbances of smell and taste;R43.8
Intervention
Intervention 1 Intervention group This group will be treated with respiratory physiotherapy or olfactory rehabilitation for 12 weeks. Intervention 2 Intervention group The second group will be treated with vitamin A tablets (10,000 units per day) along with the olfactory rehabilitation method for 12 weeks. Intervention 3 Control group The third group of patients will not receive any treatment intervention and these patients will be followed up for 12 weeks.Primary outcome:
Smell Identification. Timepoint The olfactory test is performed for 12 weeks, twice a day, each time inhaling each odor for 10 seconds. Method of measurement Aromatic kit that includes 4 main scents (eucalyptus, lemon, rose and Dianthus).Criteria
Inclusion criteria Age between 20 and 65No underlying disease including hypertension, hypo and hyperthyroidism, seizures, diabetes, asthma, Bell's palsy
Continuation of olfactory reduction for more than two weeks
Exclusion criteria Patient dissatisfaction
Prolonged exposure to some chemicals agents (detergents)
History of head trauma
History of sinus surgery or septorhinoplasty, rhinoplasty, turbinectomy and radiation therapy
Having neurodegenerative disease (Alzheimer's, Parkinson, MS, epilepsy, seizures)
Having mental disorders (schizophrenia and depression)
Having neuropsychiatric disorders (autism, Asperger's, lack of concentration and hyperactivity)
History of repeated use of the following drugsMetronidazole, benzocaine, clofibrate, amphotericin B, ampicillin, allopurinol, captopril, baclofen, codeine, carbamazepine and amphetamines.
Collection:
Clinical trial registers
Database:
ICTRP
Year:
2021
Document Type:
Clinical Trial Register
Similar
MEDLINE
...
LILACS
LIS